Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
NASDAQ:MBRX
MBRX Stock Chart & Stats
$2.24
-$0.01(-0.56%)
At close: 4:00 PM EST
$2.24
-$0.01(-0.56%)
Day’s Range― - ―
52-Week Range$2.05 - $33.00
Previous CloseN/A
Volume63.82K
Average Volume (3M)2.74M
Market Cap
$6.90M
Enterprise Value-$3.80M
Total Cash (Recent Filing)$6.70M
Total Debt (Recent Filing)$390.00K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Mar 20, 2026EPS Estimate
-6.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.02
Shares Outstanding3,079,229
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-0.25
Enterprise Value/Market Cap-0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit46.89
Enterprise Value/Ebitda0.09
Forecast
1Y Price Target
$21.00Price Target Upside837.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-7.92
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressProgress toward the targeted consent threshold for the planned unblinded interim analysis maintains momentum in the MIRACLE trial and enables the pivotal efficacy assessment upon data lock.
EfficacyPreliminary blinded Phase 3 MIRACLE data indicate a composite remission rate notably above historical cytarabine benchmarks, suggesting annamycin may deliver meaningful efficacy in relapsed or refractory AML.
Safety ProfileIndependent assessments and multiple trials report no signs of cardiotoxicity for annamycin, supporting a differentiated cardiac safety profile versus traditional anthracyclines.
Bears Say
Blinded Data UncertaintyBlinded aggregate results create uncertainty because observed signals could reflect study-wide factors rather than a clear drug effect until the unblinded readout is available.
Control-arm Confounding RiskImprovements in patient management or stronger-than-expected responses in the control arm could confound interpretation of the blinded efficacy signal and complicate regulatory assessment.
Investment Concentration RiskThe investment thesis is heavily dependent on demonstrating clinical efficacy in the MIRACLE trial, increasing exposure to a binary outcome that could markedly change valuation.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $2.05 and its highest was $33.00 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $6.90M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Mar 20, 2026 which is in 13 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Nov 17, 2025. The company reported -$17.015 earnings per share for the quarter, missing the consensus estimate of -$6.583 by -$10.432.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -6.11.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 3,079,229 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$17.015 in its last earnings report, missing expectations of -$6.583. Following the earnings report the stock price went down -2.213%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
MBRX Stock 12 Month Forecast
Average Price Target
$21.00
▲(837.50% Upside)
Technical Analysis
Ownership Overview
35.72% Insiders
2.84% Mutual Funds
<0.01% Other Institutional Investors
61.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---